Nectar Lifesciences cash flow

Latest FY26

Cash from operations: −₹349cr₹169 cr in FY25
Capital spending: ₹12.3cr−72.0% on FY25
Free cash flow: −₹361cr₹126 cr in FY25
Cash from financing: −₹767cr−₹128 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	22.8	62.4	60.7	59.1
	—	36.1	74.6	87.1	79.5
	—	−7.0	−1.9	−12.4	−1.7
	—	−0.0	0.0	0.0	0.0
	—	0.0	1.6	0.9	0.2
	—	204	−0.0	−0.2	−40.5
	—	−701	0.8	−0.5	1.3
	—	233	146	−28.5	13.2
	—	16.6	33.7	−99.6	167
	—	299	−0.2	−1.7	0.3
	—	−56.7	0.1	32.0	−20.0
	—	0.8	−0.4	−0.9	−0.0
	—	112	−8.8	53.9	−11.3
	—	1.6	−0.1	0.0	0.9
	—	−342	18.5	101	−57.9
	—	−50.4	11.0	4.4	−10.4
	—	0.0	0.0	0.0	−0.8
	—	−8.1	−8.1	8.4	−3.3
	—	−0.7	−0.0	−0.0	−0.0
	—	−2.9	0.7	0.4	0.2
	—	−18.6	0.8	1.5	0.1
Cash from operating activities
	−25.5	−87.9	−162	18.3	−42.4
	—	−261	331	206	176
	—	−349	169	225	134
	—	−349	169	225	134
Cash from investing activities
	—	12.3	43.8	29.4	30.1
	—	20.5	0.0	0.0	79.8
	—	399	0.0	0.0	0.0
	—	334	0.0	0.0	0.0
	—	0.0	0.0	0.0	0.3
	—	0.0	0.0	0.0	0.0
	—	7.0	1.5	12.4	1.7
	—	1,257	0.4	0.0	0.0
	—	1,208	−41.9	−17.0	51.7
Cash from financing activities
	—	81.0	0.0	0.0	0.0
	—	0.0	0.0	0.0	3.0
	—	649	53.3	119	109
	—	0.6	0.2	0.0	0.0
	—	—	—	−0.4	0.0
	—	36.1	74.6	87.1	79.5
	—	−767	−128	−205	−186
	—	92.9	−0.6	2.2	−0.2
	—	92.9	−0.6	2.2	−0.2
	—	—	—	19.8	17.6
Reference items
	−89.2	−60.7	−26.5	153	53.9
	−1,779.9%	—	−1.6%	9.1%	3.5%
	−361	−361	126	195	104
	—	−979	−2.4	−10.2	—
	−₹18.58	−₹18.58	₹6.47	₹10.05	₹5.33
	—	1.19×	−1.49×	44.99×	−5.53×
	—	36.1	74.6	87.1	79.5

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NECLIFE₹10.34

Nectar Lifesciences Limited

· Pharma & Health

₹ CrorePeersAAREYDRUGS NATCAPSUQ MEDICAMEQ MEDICO BALPHARMA ALPA KREBSBIO HALEOSLABSMcap ₹201 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	59.1	60.7	62.4	22.8	—
+ Finance Costs	79.5	87.1	74.6	36.1	—
+ Interest Income	-1.7	-12.4	-1.9	-7.0	—
+ Dividend Income	0.0	0.0	0.0	-0.0	—
+ Other Non-cash Items	0.2	0.9	1.6	0.0	—
+ Other — Cash Effects are Investing / Financing	-40.5	-0.2	-0.0	203.7	—
+ Other Reconciling Items	1.3	-0.5	0.8	-700.9	—
Changes in Working Capital
+ Inventories	13.2	-28.5	146.3	232.9	—
+ Trade Receivables — Current	167.4	-99.6	33.7	16.6	—
+ Trade Receivables — Non-current	0.3	-1.7	-0.2	299.3	—
+ Other Financial Assets — Current	-20.0	32.0	0.1	-56.7	—
+ Other Financial Assets — Non-current	-0.0	-0.9	-0.4	0.8	—
+ Other Current Assets	-11.3	53.9	-8.8	112.2	—
+ Other Non-current Assets	0.9	0.0	-0.1	1.6	—
+ Trade Payables — Current	-57.9	100.9	18.5	-341.7	—
+ Other Financial Liabilities — Current	-10.4	4.4	11.0	-50.4	—
+ Other Financial Liabilities — Non-current	-0.8	0.0	0.0	0.0	—
+ Other Current Liabilities	-3.3	8.4	-8.1	-8.1	—
+ Other Non-current Liabilities	-0.0	-0.0	-0.0	-0.7	—
+ Provisions — Current	0.2	0.4	0.7	-2.9	—
+ Provisions — Non-current	0.1	1.5	0.8	-18.6	—
Cash from Operating Activities
Profit Before Tax (per I/S)	-42.4	18.3	-161.5	-87.9	-25.5
+ Total Adjustments (incl. Working Capital)	176.1	206.4	331.0	-260.8	—
Cash from Operations (pre-tax)	133.7	224.7	169.4	-348.7	—
Cash from Operating Activities	133.7	224.7	169.4	-348.7	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	30.1	29.4	43.8	12.3	—
+ Disp of Fixed Assets	79.8	0.0	0.0	20.5	—
+ Acq of Investment Property	0.0	0.0	0.0	398.9	—
+ Disp of Investment Property	0.0	0.0	0.0	334.4	—
+ Sale of Investments (Equity / Debt)	0.3	0.0	0.0	0.0	—
+ Dividends Received — Investing	0.0	0.0	0.0	0.0	—
+ Interest Received — Investing	1.7	12.4	1.5	7.0	—
+ Other Inflows / (Outflows) — Investing	0.0	0.0	0.4	1,257.5	—
Cash from Investing Activities	51.7	-17.0	-41.9	1,208.1	—
Cash from Financing Activities
+ Payments for Other Equity Instruments	0.0	0.0	0.0	81.0	—
+ Proceeds from Borrowings	3.0	0.0	0.0	0.0	—
+ Repayment of Borrowings	109.1	118.7	53.3	648.8	—
+ Payment of Lease Liabilities	0.0	0.0	0.2	0.6	—
+ Payment of Finance Lease Liabilities	0.0	-0.4	—	—	—
+ Interest Paid	79.5	87.1	74.6	36.1	—
Cash from Financing Activities	-185.6	-205.4	-128.1	-766.5	—
Net Changes in Cash (pre-FX)	-0.2	2.2	-0.6	92.9	—
Net Changes in Cash	-0.2	2.2	-0.6	92.9	—
Closing Cash	17.6	19.8	—	—	—
Reference Items
EBITDA	53.9	153.1	-26.5	-60.7	-89.2
EBITDA Margin %	3.54	9.08	-1.58	—	-1,779.89
Free Cash Flow (CFO − Capex)	103.6	195.3	125.6	-361.0	-361.0
Free Cash Flow to Equity	—	-10.2	-2.4	-979.1	—
Free Cash Flow per Basic Share	5.33	10.05	6.47	-18.58	-18.58
Cash Flow to Net Income	-5.53	44.99	-1.49	1.19	—
Cash Paid for Interest	79.5	87.1	74.6	36.1	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.